Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
NEW YORK, Nov. 27, 2017 -- ImmuDyne, Inc. (OTCQB:IMMD) (“ImmuDyne” or the “Company”), a leader in the development and online marketing of OTC health and wellness products addressing large unmet needs, today announced that it has made a strategic investment and now owns 1,000,000 common shares of Blockchain Industries, Inc. (OTCMKTS:OMGT).
“ImmuDyne believes that blockchain technologies have the ability to transform the online world. We think this specific strategic investment could be a fantastic windfall for all ImmuDyne shareholders, with very little proportionate risk. Additionally, our relationship with Blockchain Industries will give us a valuable partner and exposure to new companies and technologies that can support our core business of building and marketing innovative online proprietary brands,” stated Mark McLaughlin, CEO of ImmuDyne.
About ImmuDyne
ImmuDyne, Inc. (the "Company") is a health and wellness company that develops, manufactures, and markets innovative consumer products. ImmuDyne manufactures and markets a proprietary and patent protected Yeast Beta Glucan that has been shown in thousands of clinical studies to support and regulate the human immune system. It has broad applications in skincare and as an immune support supplement. ImmuDyne PR, a majority owned subsidiary of ImmuDyne, Inc., is the digital marketing arm of ImmuDyne and is currently focused on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing ImmuDyne’s proprietary Yeast Beta Glucan ingredient (Inate MD). All of lmmudyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com
Forward-Looking Statements
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
Investor Relations Contact:
Bernard Girma
+1-949-215-7754
